Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 4/20 | 0.60 |
| ▸ | FPR2 | P25090 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | IL1RN | P18510 | 2/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16557520 | 0.93 | MME (0.55) | FPR1FPR2ALDH1A1THRBCYP2C9 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL7127847 | 0.91 | FPR1 (0.61) | FPR1FPR2MME | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL17202476 | 0.91 | FPR1 (0.61) | FPR1FPR2MME | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL9903983 | 0.91 | FPR1 (0.61) | FPR1FPR2MME | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39529 | 0.91 | FPR1 (0.61) | FPR1FPR2MME | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4969844 | 0.91 | FPR1 (0.61) | FPR1FPR2MME | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39528 | 0.91 | FPR1 (0.61) | FPR1FPR2MME | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4592799 | 0.91 | FPR1 (0.61) | FPR1FPR2MME | |
| SCHEMBL2413701 | 0.90 | FPR1 (0.60) | FPR1FPR2MME | |
| SCHEMBL14391740 | 0.90 | FPR1 (0.60) | FPR1FPR2MMEANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020042403-A1 | Use of vitamin D analogs to treat conditions related to increased oxidative stress | SERBINOVA ELENA A (US) | 2002-04-11 | — | — | US | disclosed |
| US-6262041-B1 | TOPICALLY ADMINISTERING THE COMPOUND 26, 27-HEXAFLUORO-1,25-DIHYDROXY VITAMIN D3 TO THE SKIN | BERTEK PHARMACEUTICALS, INC. | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042403-A1 | Use of vitamin D analogs to treat conditions related to increased oxidative stress | VDR, CYP24A1, CYP2R1 | FPR1 218/4885FPR2 301/4885ALDH1A1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.